2022 World Conference on Lung Cancer (ePosters)-EP08.01-046. Examination of Long-Term Administration of Pembrolizumab in Patients with Non-small Cell Lung Cancer at Our Institution

EP08.01-046. Examination of Long-Term Administration of Pembrolizumab in Patients with Non-small Cell Lung Cancer at Our Institution

Back to course

Pdf Summary

This study examined the long-term administration of pembrolizumab, an immune checkpoint inhibitor, in patients with non-small cell lung cancer. The researchers retrospectively reviewed the records of patients who received a pembrolizumab-based regimen for one year or more at their institution. Out of the 33 cases that received pembrolizumab, nine had long-term administration of one year or longer. All nine patients were male, with a median age of 68 years. The histological diagnoses varied, including squamous cell carcinoma, adenocarcinoma, and non-small cell lung cancer. The patients were at different stages of lung cancer, with some having Tumor Proportion Scores (TPS) of 50% or higher and others having TPS of 1% to 49% or 1%. None of the patients had EGFR mutation or ALK/ROS1 fusion gene mutation. <br /><br />The researchers found that patients who received long-term pembrolizumab had a higher 5-year overall survival rate compared to those who received it for less than a year. Only two patients experienced immune-related adverse events (irAE), such as hypothyroidism and adrenocortical insufficiency, and there were no grade 3 or higher side effects observed. One patient was able to continue pembrolizumab administration without any complications. The study suggests that long-term administration of pembrolizumab may provide good disease control and allow for surgical options in cases that were not previously targeted for surgery. It also indicates that even patients with low TPS can have good disease control with pembrolizumab. The researchers highlight the potential for tumor regression and downstaging, which can open up new treatment options like salvage surgery. The findings imply that the concept of surgical indications may change as more advanced lung cancer patients undergo conversion or salvage surgery. Overall, the study suggests the effectiveness and tolerability of long-term pembrolizumab administration in patients with non-small cell lung cancer.

Asset Subtitle

Kazuhito Nii

Meta Tag

Speaker Kazuhito Nii

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

pembrolizumab

immune checkpoint inhibitor

non-small cell lung cancer

long-term administration

histological diagnoses

Tumor Proportion Scores

surgical options

disease control

salvage surgery

effectiveness